Sanofi-aventis (NYSE:SNY) and Regeneron Pharmaceutical, Inc. (NASDAQ:REGN) reported Friday that they are enrolling patients in more than 10 late-stage clinical trials named Odyssey. The treatment is potentially a first-in-its-class drug that should lower cholesterol by targeting an enzyme called PCSK9. Odyssey will involve more than 22,000 patients, out of which 18,000 will participate in a trial to measure cardiovascular outcomes such as heart attacks and strokes.
Don’t Miss: Gold and Silver DODGE Market Sell-Off.
Shares of Magellan Health Services, Inc. (NASDAQ:MGLN) rise again Friday, following Thursday’s 8 percent jump, on word that the firm has been working with Credit Suisse for months, looking at strategic alternatives, which might include a potential sale. Chatter has it that the sale process has reached an advanced stage.
Novartis AG’s (NYSE:NVS) Afinitor has been okayed by the FDA, for use in combination with Aromasin, to treat certain postmenopausal women suffering from advanced breast cancer. The combination is intended for use in women who had a recurrence or progression of their cancer subsequent to treatment with Femara or Arimidex.
Don’t Miss: WellPoint Second Quarter Earnings Sneak Peek.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.